Susquehanna International Group
BCRX icon

Susquehanna International Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Susquehanna International Group’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.49M Sell
156,900
-43,400
-22% -$337K ﹤0.01% 6891
2025
Q4 		$1.56M Buy
200,300
+131,600
+192% +$951K ﹤0.01% 6150
2025
Q3 		$521K Sell
68,700
-46,700
-40% -$389K ﹤0.01% 8839
2025
Q2 		$1.03M Buy
115,400
+31,000
+37% +$289K ﹤0.01% 7347
2025
Q1 		$633K Sell
84,400
-7,500
-8% -$60.5K ﹤0.01% 8385
2024
Q4 		$691K Buy
91,900
+8,000
+10% +$60.7K ﹤0.01% 7851
2024
Q3 		$638K Sell
83,900
-23,700
-22% -$180K ﹤0.01% 7891
2024
Q2 		$665K Sell
107,600
-290,600
-73% -$1.6M ﹤0.01% 7558
2024
Q1 		$2.02M Buy
398,200
+268,700
+207% +$1.51M ﹤0.01% 5318
2023
Q4 		$776K Sell
129,500
-1,300
-1% -$7.53K ﹤0.01% 7606
2023
Q3 		$926K Sell
130,800
-22,300
-15% -$160K ﹤0.01% 6792
2023
Q2 		$1.08M Sell
153,100
-44,900
-23% -$360K ﹤0.01% 6507
2023
Q1 		$1.65M Sell
198,000
-152,500
-44% -$1.47M ﹤0.01% 5560
2022
Q4 		$4.02M Sell
350,500
-17,800
-5% -$222K ﹤0.01% 3572
2022
Q3 		$4.64M Sell
368,300
-201,100
-35% -$2.59M ﹤0.01% 3280
2022
Q2 		$6.02M Buy
569,400
+54,700
+11% +$564K ﹤0.01% 2889
2022
Q1 		$8.37M Sell
514,700
-451,400
-47% -$7.24M ﹤0.01% 2789
2021
Q4 		$13.4M Buy
966,100
+49,800
+5% +$659K ﹤0.01% 2320
2021
Q3 		$13.2M Sell
916,300
-628,000
-41% -$9.9M ﹤0.01% 2495
2021
Q2 		$24.4M Buy
1,544,300
+785,200
+103% +$10.7M ﹤0.01% 1815
2021
Q1 		$7.72M Buy
759,100
+209,000
+38% +$2.16M ﹤0.01% 3190
2020
Q4 		$4.1M Sell
550,100
-111,700
-17% -$576K ﹤0.01% 3763
2020
Q3 		$2.27M Buy
661,800
+264,500
+67% +$1.13M ﹤0.01% 4377
2020
Q2 		$1.89M Buy
397,300
+332,000
+508% +$1.33M ﹤0.01% 4595
2020
Q1 		$131K Sell
65,300
-26,800
-29% -$73.8K ﹤0.01% 9109
2019
Q4 		$318K Buy
92,100
+52,100
+130% +$131K ﹤0.01% 7899
2019
Q3 		$115K Sell
40,000
-588,000
-94% -$1.83M ﹤0.01% 9485
2019
Q2 		$2.38M Buy
628,000
+411,400
+190% +$2.48M ﹤0.01% 3841
2019
Q1 		$1.76M Buy
216,600
+184,100
+566% +$1.58M ﹤0.01% 3954
2018
Q4 		$262K Sell
32,500
-2,800
-8% -$21.8K ﹤0.01% 7241
2018
Q3 		$269K Sell
35,300
-19,100
-35% -$128K ﹤0.01% 7676
2018
Q2 		$312K Sell
54,400
-20,200
-27% -$111K ﹤0.01% 7760
2018
Q1 		$356K Buy
74,600
+30,500
+69% +$157K ﹤0.01% 7327
2017
Q4 		$217K Sell
44,100
-352,600
-89% -$1.71M ﹤0.01% 8132
2017
Q3 		$2.08M Buy
396,700
+325,500
+457% +$1.67M ﹤0.01% 3833
2017
Q2 		$396K Sell
71,200
-130,200
-65% -$793K ﹤0.01% 7068
2017
Q1 		$1.69M Sell
201,400
-215,700
-52% -$1.5M ﹤0.01% 4026
2016
Q4 		$2.64M Buy
417,100
+124,600
+43% +$648K ﹤0.01% 3486
2016
Q3 		$1.29M Buy
292,500
+272,600
+1,370% +$1.09M ﹤0.01% 4322
2016
Q2 		$57K Sell
19,900
-9,600
-33% -$29.8K ﹤0.01% 8211
2016
Q1 		$83K Sell
29,500
-237,100
-89% -$1.05M ﹤0.01% 8504
2015
Q4 		$2.75M Sell
266,600
-43,200
-14% -$430K ﹤0.01% 3458
2015
Q3 		$3.53M Buy
309,800
+111,400
+56% +$1.49M ﹤0.01% 3212
2015
Q2 		$2.96M Sell
198,400
-44,100
-18% -$501K ﹤0.01% 3877
2015
Q1 		$2.19M Sell
242,500
-60,500
-20% -$626K ﹤0.01% 4154
2014
Q4 		$3.68M Sell
303,000
-49,700
-14% -$549K ﹤0.01% 3360
2014
Q3 		$3.45M Buy
352,700
+73,200
+26% +$897K ﹤0.01% 3633
2014
Q2 		$3.56M Sell
279,500
-353,200
-56% -$3.44M ﹤0.01% 3619
2014
Q1 		$6.69M Buy
632,700
+271,300
+75% +$2.89M ﹤0.01% 2504
2013
Q4 		$2.75M Buy
361,400
+183,100
+103% +$1.16M ﹤0.01% 3773
2013
Q3 		$1.3M Buy
178,300
+94,600
+113% +$480K ﹤0.01% 4842
2013
Q2 		$130K Buy
+83,700
New +$144K ﹤0.01% 7698

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Susquehanna International Group's BCRX Position: Q1 2026 in Review

Susquehanna International Group increased its BioCryst Pharmaceuticals (BCRX) stake by 319% in Q1 2026, buying an estimated $16.6M and bringing the position to 2,815,304 shares worth $26.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1876.

Susquehanna International Group first reported a position in BCRX in Q2 2013 and has held it in 42 quarters since. The position peaked at $27.6M in Q4 2021. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Susquehanna International Group held 2,815,304 shares of BioCryst Pharmaceuticals worth $26.8M as of Q1 2026.
  • Susquehanna International Group bought 2,143,611 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $16.6M.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #1876 holding.
  • Susquehanna International Group first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 42 quarters since.
  • Susquehanna International Group's BioCryst Pharmaceuticals position peaked at $27.6M in Q4 2021.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.